Depo-Provera Daubert Motion: 2026 Lawsuit Update (MDL 3140)

I’m Mason Arnao. Years of work in data systems, technology infrastructure, and digital advocacy have shown me how the Depo-Provera Daubert motion fight and the wider 2026 litigation affect real people trying to navigate complicated legal and medical systems. As publisher of LegalLawsuit.com and President of Waypoint Software, I’ve spent more than 20 years building ways to connect people with information that matters. This guide explains what’s happening and how to protect your rights.

The Depo-Provera lawsuit has reached a turning point in 2026. With roughly 3,790 plaintiffs consolidated in federal MDL 3140, the court is weighing Daubert motions that could reshape the litigation. Women diagnosed with meningioma brain tumors after Depo-Provera (medroxyprogesterone acetate) injections claim Pfizer and its subsidiary Pharmacia didn’t adequately warn them of the risk, despite years of research tying synthetic progestins to meningioma growth. If you or someone you love received Depo-Provera shots and later developed a meningioma, you may be entitled to compensation. This guide covers the latest developments, who qualifies, and how to protect your rights before your filing deadline passes.

Depo-Provera Daubert Motion: The Latest 2026 Developments

The Depo-Provera lawsuit is entering one of its most important stages. In MDL 3140, the court has scheduled Daubert proceedings, the gatekeeping process federal judges use to decide whether expert scientific testimony is reliable enough for a jury. The result matters enormously: if plaintiffs’ experts survive the Daubert motions, Pfizer could face bellwether trials. The science behind the Depo-Provera meningioma link has grown considerably in recent years. A widely cited 2024 study in the British Medical Journal found that women who used injectable progestogen contraceptives, including Depo-Provera, had a significantly higher risk of intracranial meningioma than non-users, and plaintiffs are expected to lean heavily on it for causation. Research cataloged by the National Institutes of Health describes meningiomas as the most common primary brain tumor and recognizes hormonal factors, especially progestin exposure, as important risk factors. Pfizer’s defense attacks the strength of the epidemiology, arguing that the BMJ study and other research plaintiffs cite have methodological flaws, and it has asked the court to exclude several plaintiff experts as failing Daubert’s reliability standard. Plaintiffs respond that years of peer-reviewed research establish a biologically plausible, statistically significant link that easily clears that bar. The stakes are high. If plaintiffs win the Daubert fight, bellwether trials, cases chosen to test each side’s theories before a jury, are expected to follow, and their verdicts typically shape any global settlement. As of this update, reported filings in early 2026 included defense motions targeting plaintiffs’ general causation experts and detailed opposition briefs from plaintiffs, with rulings expected to determine any trial schedule. Meanwhile, new cases keep arriving, many from women who received Depo-Provera shots over long periods, particularly five years or more, and later needed surgery, radiation, or other serious treatment for meningiomas. Injuries in this MDL tend to be serious, and the most severe cases are expected to carry the highest values.

What Is a Meningioma, and How Is Depo-Provera Linked to It?

Understanding the lawsuit starts with the injury at its core. A meningioma is a tumor that forms in the meninges, the three protective layers of tissue around the brain and spinal cord. Most are benign, but that doesn’t make them harmless: as they grow, they press on the brain and nearby structures and can cause disabling, life-changing symptoms. These include severe, ongoing headaches; vision problems such as blurring, double vision, or lost peripheral vision; hearing loss or ringing in the ears; memory and thinking problems; weakness or numbness in the limbs; seizures; and sometimes personality changes or depression. Many patients need a craniotomy to remove the tumor, often followed by radiation to keep it from returning, and recovery can take months or years, with some people left with permanent neurological deficits. Researchers increasingly understand why Depo-Provera may matter. Meningiomas carry progesterone receptors, making them sensitive to hormones, and medroxyprogesterone acetate (MPA), the active ingredient in Depo-Provera, is a synthetic progestin that binds those receptors and may fuel tumor growth. The longer a woman uses the drug and the higher her cumulative dose, the greater the potential for a meningioma to develop or grow faster. Peer-reviewed studies have repeatedly found higher meningioma risk among women using high-dose progestins, and the 2024 BMJ study stood out because it looked specifically at injectable progestins, the form Depo-Provera takes, and found the risk was greatest after more than five years of use. Pfizer’s critics argue the company knew or should have known about this risk for years and failed to put adequate warnings in the prescribing information, and that it had a duty to update the label as the science developed. The regulatory picture has been shifting, so check the current FDA prescribing information linked on this page for the latest warning language. For women diagnosed with meningioma after using Depo-Provera, the emotional and financial burden is heavy; many went through frightening brain surgery never suspecting that a contraceptive they trusted might be involved. The Depo-Provera lawsuit gives them a way to hold Pfizer accountable and seek compensation for pain, medical bills, lost income, and reduced quality of life.

Who Qualifies for a Depo-Provera Lawsuit?

If you received Depo-Provera (medroxyprogesterone acetate) injections and were later diagnosed with a meningioma, you may be able to join the Depo-Provera litigation. Eligibility depends on how you used the drug and your diagnosis. Attorneys typically look at the following:

• You received Depo-Provera shots, usually given every three months on the standard 150 mg/mL schedule
• You used it for a meaningful period, most often a year or longer, with stronger cases involving three years or more
• You have a confirmed meningioma diagnosis from an MRI, CT scan, biopsy, or surgical pathology report
• The diagnosis followed your Depo-Provera use, or the tumor grew or progressed while you were using it
• The meningioma needed medical care, whether monitored watchful waiting with documented symptoms, surgery, radiation (stereotactic radiosurgery or external beam), or a mix
• You’re within the statute of limitations, which varies by state but often runs 2-3 years from when you learned, or should have learned, of the possible link
• You live in the U.S., since MDL 3140 covers claims in U.S. federal courts

More severe cases, those involving surgery, permanent neurological damage, or major effects on quality of life, are generally valued higher. If you’re not sure whether you qualify, call 833-333-0905 for a free, confidential case review; a specialist can look at your Depo-Provera history and medical records to see whether you may have a claim. Relatives of someone who died may also be able to bring a wrongful death claim in some situations. If a loved one passed away from complications of a meningioma that developed after Depo-Provera use, you may still be able to seek compensation on their behalf, and an attorney can explain your state’s rules.

What Drives Depo-Provera Settlement Value

In July 2026 Pfizer signed a Master Settlement Agreement for eligible MDL 3140 claims, following a June 2026 agreement in principle, but the payout tiers have not been made public, so any dollar figure you see quoted online is speculation. The Depo-Provera settlement calculator on Legal Lawsuit offers an educational estimate, and the factors below are what typically separate stronger claims from weaker ones. Most serious cases: meningiomas that required a craniotomy or other major surgery, caused permanent deficits such as vision or hearing loss, cognitive problems, or weakness, needed radiation, or seriously reduced quality of life, especially with long-term use (5+ years) or large or recurring tumors. Moderate cases: tumors that needed surgery or other significant treatment with a largely successful recovery, or monitored tumors causing documented symptoms that affect daily life, often with 2–5 years of use. Less severe cases: meningiomas found incidentally that need only monitoring and haven’t caused major symptoms, or shorter use with few or no symptoms. Actual values will depend on your medical history, how strong the causal link is in your case, where you live, how the litigation unfolds, and the terms of any global agreement. To talk through your own case, call 833-333-0905. Damages in these claims usually include past and future medical costs (surgery, radiation, follow-up, medication), lost income and earning capacity, pain and suffering, emotional distress, loss of enjoyment of life, and possibly punitive damages if Pfizer’s conduct is found especially egregious. Our general settlement calculator offers broader context on how mass tort values are calculated.

How to File a Depo-Provera Lawsuit in 2026

With an experienced mass tort attorney, filing a Depo-Provera claim is straightforward. Here’s what to expect step by step:

1. Free case review (day 1): call 833-333-0905 or fill out an online intake form, and a specialist will look at your Depo-Provera history and meningioma diagnosis to see whether you likely qualify.
2. Attorney match (days 1–3): if your case looks viable, you’ll be connected with a mass tort attorney in our network who handles Depo-Provera cases on contingency, so you pay nothing unless you’re compensated.
3. Collecting records (weeks 1–4): your lawyer gathers prescription and injection records, MRI or CT imaging, surgical and pathology reports, and other relevant medical files.
4. Filing the complaint (weeks 4–8): your attorney prepares and files a formal complaint in federal court, and the case joins MDL 3140 alongside thousands of similar claims.
5. Discovery (months 2–18+): both sides trade documents and take depositions; in an MDL, much of this happens at the group level, so individual plaintiffs often aren’t deposed.
6. Settlement or trial: once bellwether verdicts come in, global settlement talks usually speed up, and if a deal is reached your attorney will explain the terms and advise you on accepting.

Try Our Free Depo-Provera Settlement Calculator

For an educational estimate of your claim’s value, visit the Depo-Provera settlement calculator and enter your treatment history, how long you used Depo-Provera, and how severe your injury is.

MDL 3140 Status, Daubert Rulings, and Timeline

MDL 3140, In Re: Depo-Provera (Medroxyprogesterone Acetate) Products Liability Litigation, is the federal proceeding that consolidates these cases. Here is the picture as of this update: Case count: roughly 3,790 individual cases pending, with new ones added weekly, and many observers expect the total to keep climbing before any global resolution. Daubert motions: briefing on both sides’ Daubert motions has been completed, and the rulings will decide which experts may testify at trial. Bellwether selection: the parties have proposed potential bellwether cases, and if the Daubert rulings favor plaintiffs, trials could follow. Settlement status: Pfizer and plaintiffs’ leadership announced a global agreement in principle in June 2026 and signed a Master Settlement Agreement in July 2026 for eligible federal claims; the court has appointed a settlement administrator, and individual award amounts have not been disclosed. If you used Depo-Provera and developed a meningioma, file as soon as you can, since statutes of limitations in most states run 2–3 years from when you discovered, or should have discovered, the possible link. Call 833-333-0905 to get started today.

Depo-Provera Lawsuit: Common Questions for 2026

About the Author

Mason Arnao is President and Managing Partner of Waypoint Software, LLC, a South Florida software development and digital advocacy company. With more than 20 years in data systems, technology infrastructure, and digital research, he has studied how pharmaceutical failures like the Depo-Provera meningioma litigation affect ordinary people facing complicated legal systems. As publisher of LegalLawsuit.com, he is dedicated to giving injured people the information and legal resources they need to act.

Last Updated: July 16, 2026 | Reviewed by: Legal Lawsuit Editorial Team | Primary Sources: JPML MDL docket records and court filings.